奇正藏药(002287) - 2024 Q2 - 季度业绩

Financial Performance - The company achieved total operating revenue of CNY 1,009,833,674.27, representing a 21.70% increase compared to the same period last year[3] - Operating profit for the period was CNY 367,188,586.70, up 7.85% year-on-year[3] - Net profit attributable to shareholders was CNY 326,055,048.13, reflecting a 4.42% increase from the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 227,631,806.32, a growth of 4.30% compared to last year[3] - Basic earnings per share increased to CNY 0.6150, up 4.36% from CNY 0.5893 in the same period last year[3] Assets and Equity - Total assets at the end of the reporting period were CNY 6,748,600,595.37, a 7.15% increase from the beginning of the period[3] - Shareholders' equity attributable to the company was CNY 3,792,936,009.51, showing a 1.95% increase[3] - The company's weighted average return on equity decreased to 8.49%, down 0.45 percentage points from the previous year[3] Future Outlook - The company did not disclose any performance forecasts for the first half of 2024 as of the announcement date[6] Operational Conditions - The company’s production and operational conditions were reported as normal during the period[5]